Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/31306
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDizdar, Oğuzhan Sıtkı-
dc.contributor.authorKoca, Nizameddin-
dc.contributor.authorAydın, Taner-
dc.date.accessioned2023-03-02T12:33:32Z-
dc.date.available2023-03-02T12:33:32Z-
dc.date.issued2017-06-
dc.identifier.citationCander, S. vd. (2017). ''Assessing the impact of insulin glargine and detemir treatment to serum total IGF1 levels in the insulin-naive type 2 diabetic patients''. Metabolic Syndrome and Related Disorders, 15(5), 220-225.en_US
dc.identifier.issn1540-4196-
dc.identifier.issn1557-8518-
dc.identifier.urihttps://doi.org/10.1089/met.2017.0005-
dc.identifier.urihttps://www.liebertpub.com/doi/10.1089/met.2017.0005-
dc.identifier.urihttp://hdl.handle.net/11452/31306-
dc.description.abstractAim: The mitogenic potential of analog insulins due to their different insulin-like growth factor-1 (IGF1) receptor affinity is a situation that causes concern related to cancer risk. We aimed to examine the changes in the serum IGF1 levels formed by insulin glargine and detemir in the insulin-naive type 2 diabetic patients. Methods: The serum total IGF1 levels of the 62 insulin-naive type 2 diabetic patients were studied before and after 12 weeks of the started treatment with basal insulin analogs. Twenty-two and twenty patients (Group I and II) using the single-dose and double-dose insulin detemir and twenty patients (Group III) using insulin glargine were evaluated. Results: In Group I and Group II, the average 8.5% and 0.1% increases and in the Group III, 6.5% decreases were determined in the IGF1 values. The IGF1 changes were significant in the men but not in the women. Conclusion: In our study, it was determined that the insulin glargine depressed the serum IGF1 levels much more when compared to the insulin detemir. This result can be evaluated as the in vivo reflection of the in vitro findings related to the fact that the IGF1 receptor affinity of the glargine is higher.en_US
dc.language.isoenen_US
dc.publisherMary Ann Lieberten_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectResearch & experimental medicineen_US
dc.subjectInsulin analogsen_US
dc.subjectDetemiren_US
dc.subjectGlargineen_US
dc.subjectIGF1en_US
dc.subjectDiabetescanceren_US
dc.subjectGrowth-factor-Ien_US
dc.subjectAnalogsen_US
dc.subjectCanceren_US
dc.subjectReceptoren_US
dc.subjectBindingen_US
dc.subjectMalignanciesen_US
dc.subjectMetabolitesen_US
dc.subjectPopulationen_US
dc.subjectMetforminen_US
dc.subjectTherapyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshBiomarkersen_US
dc.subject.meshBlood glucoseen_US
dc.subject.meshDiabetes mellitusen_US
dc.subject.meshType 2en_US
dc.subject.meshDown-regulationen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlycated hemoglobin Aen_US
dc.subject.meshHumansen_US
dc.subject.meshHypoglycemic agentsen_US
dc.subject.meshInsulin detemiren_US
dc.subject.meshInsulin glargineen_US
dc.subject.meshInsulin-like growth factor Ien_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshTime factorsen_US
dc.subject.meshTreatment outcomeen_US
dc.titleAssessing the impact of insulin glargine and detemir treatment to serum total IGF1 levels in the insulin-naive type 2 diabetic patientsen_US
dc.typeArticleen_US
dc.identifier.wos000401726400003tr_TR
dc.identifier.scopus2-s2.0-85019883899tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-2593-7196tr_TR
dc.identifier.startpage220tr_TR
dc.identifier.endpage225tr_TR
dc.identifier.volume15tr_TR
dc.identifier.issue5tr_TR
dc.relation.journalMetabolic Syndrome and Related Disordersen_US
dc.contributor.buuauthorCander, Soner-
dc.contributor.buuauthorGül, Özen Öz-
dc.contributor.buuauthorSarandöl, Emre-
dc.contributor.buuauthorErsoy, Canan-
dc.contributor.researcheridAAI-1005-2021tr_TR
dc.contributor.researcheridABE-1716-2020tr_TR
dc.contributor.researcheridAAH-8861-2021tr_TR
dc.relation.collaborationSanayitr_TR
dc.identifier.pubmed28394183tr_TR
dc.subject.wosMedicine, research & experimentalen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ3en_US
dc.contributor.scopusid25027068600tr_TR
dc.contributor.scopusid26040787100tr_TR
dc.contributor.scopusid55943324800tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.subject.scopusDiabetes Mellitus; Biguanide Derivative; Cancer Risken_US
dc.subject.emtreeInsulin detemiren_US
dc.subject.emtreeInsulin glargineen_US
dc.subject.emtreeAntidiabetic agenten_US
dc.subject.emtreeBiological markeren_US
dc.subject.emtreeGlycosylated hemoglobinen_US
dc.subject.emtreeHemoglobin A1c protein, humanen_US
dc.subject.emtreeIGF1 protein, humanen_US
dc.subject.emtreeInsulin detemiren_US
dc.subject.emtreeInsulin glargineen_US
dc.subject.emtreeSomatomedin Cen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDiabetic patienten_US
dc.subject.emtreeDrug screeningen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeIn vivo studyen_US
dc.subject.emtreeInsulin treatmenten_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProtein blood levelen_US
dc.subject.emtreeSingle drug doseen_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeBlooden_US
dc.subject.emtreeComparative studyen_US
dc.subject.emtreeDown regulationen_US
dc.subject.emtreeDrug effectsen_US
dc.subject.emtreeGlucose blood levelen_US
dc.subject.emtreeMetabolismen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreeTime factoren_US
dc.subject.emtreeTreatment outcomeen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.